Xenon Pharmaceuticals' Regulatory Worry: A Harbinger for Mental Health Research?
The news of Xenon Pharmaceuticals pausing new patient enrollment in its clinical trials for azetukalner, a potential treatment for major depressive disorder, has sent shockwaves through the biotech sector.
The stock's precipitous drop, with shares trading nearly 40% below their year to date high, is a sobering reminder of the risks and uncertainties that accompany psychiatric research.